SCHEMBL23536457

SCHEMBL23536457

Cn1c(=O)[nH]c2cccc(N3CCN(C(=O)O)C(C(C)(C)C)C3)c21

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFER P55789 1/20 0.34
USP2 O75604 2/20 0.34
MAPT P10636 2/20 0.34
SLC6A7 Q99884 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
ALOX15 P16050 2/20 0.34
ADORA3 P0DMS8 1/20 0.33
ADORA2A P29274 1/20 0.33
ADORA2B P29275 1/20 0.33
ADORA1 P30542 1/20 0.33
LMNA P02545 1/20 0.33
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
RBP4 P02753 2/20 0.32
DAO P14920 1/20 0.32
NR1H2 P55055 1/20 0.32
HTR7 P34969 1/20 0.32
HTR1A P08908 3/20 0.32
DRD2 P14416 2/20 0.32
DRD3 P35462 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23536513 0.84 USP2 (0.33) GFERUSP2MAPTNPSR1ALOX15
SCHEMBL22836372 0.79 HTR1A (0.33) USP2MAPTNPSR1ALOX15DAO
SCHEMBL25337092 0.77 SSTR1 (0.37) HTR1ADRD2
SCHEMBL26644694 0.77 SSTR1 (0.37) HTR1ADRD2
SCHEMBL25339143 0.76 ACHE (0.30)
SCHEMBL22835497 0.75 DAO (0.36) NPSR1ADORA3ADORA2AADORA2BADORA1
SCHEMBL4558300 0.75 SLC6A9 (0.44) USP2SLC6A7LMNAHTR7HTR1A
SCHEMBL30881604 0.74 ADRA2C (0.45) USP2MAPTSLC6A7NPSR1MEN1
SCHEMBL17491559 0.74 ADRA2C (0.45) USP2MAPTSLC6A7NPSR1MEN1
SCHEMBL3338682 0.74 GFER (0.42) GFERMAPTLMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234953-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-07-27 US disclosed
US-11591332-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-02-28 US disclosed
US-20220340570-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2022-10-27 US disclosed
WO-2021127283-A2 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234953-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 GFER 2248/4885USP2 141/4885MAPT 2459/4885
US-11591332-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 GFER 2248/4885USP2 141/4885MAPT 2459/4885
US-20220340570-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 GFER 2248/4885USP2 141/4885MAPT 2459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.